22 Jun - 26 Jun 2022

15th Annual World Congress on Pulmonary Vascular Disease

Event

Cereno will present the abstract “Investigation of efficacy, safety and optimal dose of CS1 in subjects with pulmonary arterial hypertension: a prospective, randomized, multicenter, parallel-group phase II study” at the 15th Annual World Congress on Pulmonary Vascular Disease in Athens, Greece, on June 22-26, 2022. It’s organized by the Pulmonary Vascular Research Institute (PVRI).

The abstract is a collaboration between Cereno, Dr. Raymond Benza, global PAH key opinion leader and principal investigator (PI) for the Phase II study and study collaborator Abbott. The abstract will be presented as a poster by Dr. Raymond Benza.

Share